|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM215507088 |
| 003 |
DE-627 |
| 005 |
20231224025650.0 |
| 007 |
tu |
| 008 |
231224s2012 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed24n0718.xml
|
| 035 |
|
|
|a (DE-627)NLM215507088
|
| 035 |
|
|
|a (NLM)22343736
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Saitou, Yoshitaka
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Analysis of prognostic factor in 52 castration-resistant prostate cancer treated with docetaxel
|
| 264 |
|
1 |
|c 2012
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 10.04.2012
|
| 500 |
|
|
|a Date Revised 01.12.2018
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a The prognostic factor was retrospectively analyzed in 52 castration-resistant prostate cancer treated with docetaxel (DTX) in our institutions from April, 2006 to August, 2009. The treatment outcomes were decided with prostate specific antigen (PSA) progression-free survival and overall survival. These were calculated by Kaplan-Meier methods and tested with Log-rank test. Median PSA progression-free survival was 8.8 months and median overall survival was 24.1 months. Prognostic factors on PSA progression were PSA value before DTX treatment and rate of PSA decrement after DTX treatment. Prognostic factors on overall survival were Gleason score (GS), PSA value before DTX treatment, rate of PSA decrement after DTX treatment and positive of bone metastasis in Log-rank test. Odds ratio of PSA ≧20 ng/ml before DTX treatment was 2.99 and PSA decreasing rate < 30% was 3.65. These were statistically significant (p < 0.001) risk factors in the overall survival
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Antineoplastic Agents
|2 NLM
|
| 650 |
|
7 |
|a Taxoids
|2 NLM
|
| 650 |
|
7 |
|a Docetaxel
|2 NLM
|
| 650 |
|
7 |
|a 15H5577CQD
|2 NLM
|
| 650 |
|
7 |
|a Prostate-Specific Antigen
|2 NLM
|
| 650 |
|
7 |
|a EC 3.4.21.77
|2 NLM
|
| 700 |
1 |
|
|a Hatanaka, Yuji
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Imanishi, Masaaki
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ohzeki, Takayuki
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hashimoto, Kiyoshi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sugimoto, Koichi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Esa, Atsunobu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kajikawa, Hiroshi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yasuda, Muneo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yamamoto, Yutaka
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Uemura, Hirotsugu
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 58(2012), 1 vom: 07. Jan., Seite 7-11
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:58
|g year:2012
|g number:1
|g day:07
|g month:01
|g pages:7-11
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 58
|j 2012
|e 1
|b 07
|c 01
|h 7-11
|